The DOI matches its Crossref record; 234 of the 236 references it cites were found in a registry or an index.
p21 in cancer: intricate networks and multiple activities
Open accessAbstract
One of the main engines that drives cellular transformation is the loss of proper control of the mammalian cell cycle. The cyclin-dependent kinase inhibitor p21 (also known as p21WAF1/Cip1) promotes cell cycle arrest in response to many stimuli. It is well positioned to function as both a sensor and an effector of multiple anti-proliferative signals. This Review focuses on recent advances in our understanding of the regulation of p21 and its biological functions with emphasis on its p53-independent tumour suppressor activities and paradoxical tumour-promoting activities, and their implications in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“p21 is a potent cell-cycle inhibitor (39)”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [39]
In the citing paper
“CDKN1A (p21, WAF1, CIP1) was among the first p53 target genes11, 12 to be identified and is now recognized as an encoder for a major cell cycle checkpoint control protein.145”
From Census and evaluation of p53 target genes (2017) · cites this paper as [145]
In the citing paper
“As p21 is rarely genetically affected in cancers [1,124]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [1]
In the citing paper
“Members of the Krüppel-like factor (KLF) transcription factor (TF) family can activate the CDKN1A gene by cooperating with p300-CREBBP (Aliouat-Denis et al., 2005; Abbas and Dutta, 2009).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Abbas and Dutta, 2009
In the citing paper
“p21WAF1/CIP1 can also be activated by p53 independent mechanisms by other stimulators such as nuclear receptors including androgen, vitamin D and retinoid receptors.”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Abbas and Dutta, 2009
In the citing paper
“Although this is the first detectable event, it is more likely that main role of p21 lies in its capacity to trigger pRb-mediated repression of cell cycle regulators (Fig. 2, for more information on p21 functions (see ref. 98 ).”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [98]
In the citing paper
“For example, cyclin-dependent kinase inhibitor 1A (CDKN1A), a tumor suppressor that is downregulated in multiple cancers (106), is targeted by at least 28 miRNAs and many of which are upregulated together in cancers where CDKN1A has been implicated (107).”
From Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation (2018) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“CDK1, at least in some tissues, may be the crucial target of p21 in tumorigenesi”
BackgroundRequirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Xu, X., Yuan, G., Li, Q., Shan, S.-L., & Jiang, S. (2012) · Hepatogastroenterology · doi:10.5754/hge12404 · Cited by 1,825
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Recent work suggests that tumour regression can be achieved through the reactivation of senescence, for example by restoring p53 functio”
BackgroundPCNA, the Maestro of the Replication Fork
Moldovan, G.-L., Pfander, B., & Jentsch, S. (2007) · Cell · doi:10.1016/j.cell.2007.05.003 · Cited by 1,796
Cellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
Flagged first, then by citations
2 of the 236 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Martin-Caballero, J., Flores, J. M., Garcia-Palencia, P. & Serrano, M. Tumor susceptibility of p21Waf1/Cip1-deficient mice. Cancer Res. 61, 6234–6238 (2001). This study demonstrates that deletion of Cdkn1a in mice results in spontaneous tumours but with late onset.
Cited by
Sorted by citations
Items 601–700 of 1,005
Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer
He, Q., Xue, S., Tan, Y., Zhang, L., Shao, Q., Xing, L., Li, Y., Xiang, T., Luo, X., & Ren, G. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.004 · Cited by 47
Alves, A. P. N. R., Fernandes, J. C., Fenerich, B. A., Coelho‐Silva, J. L., Scheucher, P. S., Simões, B. P., Rego, E. M., Ridley, A. J., Machado‐Neto, J. A., & Traina, F. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.030 · Cited by 47
Lehman, S. L., Cerniglia, G. J., Johannes, G. J., Ye, J., Ryeom, S. W., & Koumenis, C. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005212 · Cited by 50
Ras signaling is essential for skin development
Drosten, M., Lechuga, C. G., & Barbacid, M. (2014) · Oncogene · doi:10.1038/onc.2013.254 · Cited by 46
Lan, Y., Lou, J., Hu, J., Yu, Z., Lyu, W., & Zhang, B. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0164 · Cited by 46
An improved imaging system that corrects MS2-induced RNA destabilization
Li, W., Maekiniemi, A., Sato, H., Osman, C., & Singer, R. H. (2022) · Nature Methods · doi:10.1038/s41592-022-01658-1 · Cited by 46
Topical Application of Ochratoxin A Causes DNA Damage and Tumor Initiation in Mouse Skin
Kumar, R., Ansari, K. M., Chaudhari, B. P., Dhawan, A., Dwivedi, P. D., Jain, S. K., & Das, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047280 · Cited by 46
YAO, M., Yang, J., Cao, L., ZHANG, L., QU, S., & Gao, H. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2153 · Cited by 46
S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest
Sapkota, D., Costea, D. E., Blø, M., Bruland, O., Lorens, J. B., Vasstrand, E. N., & Ibrahim, S. O. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.10.001 · Cited by 46
Chen, P., O’Neal, J. F., Ebelt, N. D., Cantrell, M. A., Mitra, S., Nasrazadani, A., Vandenbroek, T. L., Heasley, L. E., & Berg, C. L. V. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010443 · Cited by 47
Shibata, E., Abbas, T., Huang, X., Wohlschlegel, J. A., & Dutta, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05496-11 · Cited by 46
Self-citationYamada, K., Ono, M., Perkins, N. D., Rocha, S., & Lamond, A. I. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.12.023 · Cited by 45
Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy
Ohkoshi, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i42.12150 · Cited by 46
Chaudhary, S., Madhukrishna, B., Adhya, A. K., Keshari, S., & Mishra, S. K. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.12 · Cited by 46
Liu, X., Song, X., Lu, J., Chen, X., Liang, E., Liu, X., Zhang, M., Zhang, Y., Du, Z., & Zhao, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11225 · Cited by 46
Long non-coding RNAs associated with non-small cell lung cancer
Zhan, Y., Zang, H., Feng, J., Lu, J., Chen, L., & Fan, S. (2017) · Oncotarget · doi:10.18632/oncotarget.20088 · Cited by 46
Terzuoli, E., Nannelli, G., Frosini, M., Giachetti, A., Ziche, M., & Donnini, S. (2017) · Oncotarget · doi:10.18632/oncotarget.20544 · Cited by 47
PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma
Ghannam-Shahbari, D., Jacob, E., Kakun, R. R., Wasserman, T., Korsensky, L., Sternfeld, O., Kagan, J., Bublik, D. R., Aviel‐Ronen, S., Levanon, K., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0040-z · Cited by 45
Wang, Y., Qiu, C., Lü, N., Liu, Z., Jin, C., Sun, C., Bu, H., Yu, H., Dongol, S., & Kong, B. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4359 · Cited by 46
Functional relevance of SATB1 in immune regulation and tumorigenesis
Sunkara, K., Gupta, G., Hansbro, P. M., Dua, K., & Bebawy, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.045 · Cited by 46
Orlowska, E., Babak, M. V., Dömötör, O., Enyedy, É. A., Rapta, P., Zalibera, M., Bučinský, L., Malček, M., Govind, C., Karunakaran, V., et al. (2018) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b01341 · Cited by 46
A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer
Miller, J. J., Gaiddon, C., & Storr, T. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00163e · Cited by 47
Oncogenic viruses and chemoresistance: What do we know?
Nahand, J. S., Rabiei, N., Fathazam, R., Taghizadieh, M., Ebrahimi, M. S., Mahjoubin‐Tehran, M., Baghi, H. B., Khatami, A., Abbasi‐Kolli, M., Mirzaei, H. R., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105730 · Cited by 45
Turesson, I., Nyman, J., Qvarnström, F., Simonsson, M., Book, M., Hermansson, I., Sigurðardóttir, S., & Johansson, K.-A. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.10.007 · Cited by 47
Sheng, C., Mendler, I.-H., Rieke, S., Snyder, P., Jentsch, M., Friedrich, D., Drossel, B., & Loewer, A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.031 · Cited by 45
Allan, G., Ouadid-Ahidouch, H., Sanchez-Fernandez, E. M., Risquez-Cuadro, R., Fernandez, J. M. G., Ortiz-Mellet, C., & Ahidouch, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076411 · Cited by 45
Anticancer Potential of Natural Chalcones: In Vitro and In Vivo Evidence
Michalková, R., Mirossay, L., Kello, M., Mojžišová, G., Baloghová, J., Podracka, A., & Mojžíš, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210354 · Cited by 45
Pedroza-Saavedra, A., Lam, E. W. ‐., Esquivel-Guadarrama, F. R., & Gutiérrez‐Xicoténcatl, L. (2010) · Virology · doi:10.1016/j.virol.2010.01.009 · Cited by 45
Nekrasova, T., & Minden, A. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23092 · Cited by 45
Dörsam, B., Göder, A., Seiwert, N., Kaina, B., & Fahrer, J. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1434-0 · Cited by 49
Combined loss of p21waf1/cip1 and p27kip1 enhances tumorigenesis in mice
García-Fernández, R. A., Garcı́a, P., Sánchez, M. A. M., Gil‐Gómez, G., Sánchez, B., Rollán, E., Martín‐Caballero, J., & Flores, J. M. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.133 · Cited by 46
p21Waf1/Cip1 deficiency causes multiple mitotic defects in tumor cells
Kreis, N., Sanhaji, M., Rieger, M. A., Louwen, F., & Yuan, J. (2013) · Oncogene · doi:10.1038/onc.2013.518 · Cited by 45
Lu, D., Han, C. Q., & Wu, T. (2013) · Oncogene · doi:10.1038/onc.2013.69 · Cited by 45
Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3
Shi, Z., Li, Z., Li, Z., Cheng, K., Du, Y., Fu, H., & Khuri, F. R. (2014) · Oncogene · doi:10.1038/onc.2014.171 · Cited by 45
Ye, J., Yao, Y., Song, Q., Li, S., Hu, Z., Yu, Y., Hu, C., Da, X., Li, H., Chen, Q., et al. (2016) · Scientific Reports · doi:10.1038/srep34034 · Cited by 45
Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer
Mustachio, L. M., Lu, Y., Tafe, L. J., Memoli, V. A., Rodriguez‐Canales, J., Mino, B., Villalobos, P. A., Wistuba, I. I., Katayama, H., Hanash, S., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0369 · Cited by 45
Nrf2: a potential therapeutic target for naturally occurring anticancer drugs?
Catanzaro, E., Calcabrini, C., Turrini, E., Sestili, P., & Fimognari, C. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1351549 · Cited by 45
SNHG16: A Novel Long-Non Coding RNA in Human Cancers
Yang, M., & Wei, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s231630 · Cited by 45
Attanzio, A., D’Agostino, S., Busà, R., Frazzitta, A., Rubino, S., Girasolo, M. A., Sabatino, P., & Tesoriere, L. (2020) · Molecules · doi:10.3390/molecules25040859 · Cited by 45
Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer
Goel, B., Tripathi, N., Bhardwaj, N., & Jain, S. K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200516152756 · Cited by 45
Anticancer effects and potential mechanisms of ginsenoside Rh2 in various cancer types (Review)
Zhang, H., Park, S., Huang, H., Kim, E., Yi, J., Choi, S., Ryoo, Z. Y., & Kim, M.-O. (2021) · Oncology Reports · doi:10.3892/or.2021.7984 · Cited by 45
Molani‐Gol, R., & Kheirouri, S. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.1897631 · Cited by 49
Pustovalova, M. V., Blokhina, T., Alhaddad, L., Chigasova, A. K., Chuprov‐Netochin, R. N., Veviorskiy, A., Filkov, G. I., Osipov, A. N., & Leonov, S. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094922 · Cited by 46
Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations
Yan, H. Y., Talty, R., Jain, A., Cai, Y. A., Zheng, J., Shen, X., Muca, E., Paty, P. B., Bosenberg, M., Khan, S. A., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102699 · Cited by 44
Bland, P. J., Saville, H., Wai, P. T., Curnow, L., Muirhead, G., Nieminuszczy, J., Ravindran, N., John, M. B., Hedayat, S., Barker, H. E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01460-5 · Cited by 48
PAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesis
Wang, G., Song, Y., Liu, T., Wang, C., Zhang, Q. H., Liu, F., Cai, X., Miao, Z., Xu, H., Xu, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3185 · Cited by 44
By recruiting HDAC1, MORC2 suppresses p21Waf1/Cip1 in gastric cancer
Zhang, Q. H., Song, Y., Chen, W., Wang, X., Miao, Z., Cao, L., Feng, L., & Wang, G. (2015) · Oncotarget · doi:10.18632/oncotarget.3889 · Cited by 44
Modeling the Basal Dynamics of P53 System
Sun, T., Yang, W., Liu, J., & Shen, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027882 · Cited by 43
Chk1 and Wee1 control genotoxic-stress induced G2–M arrest in melanoma cells
Vera, J., Raatz, Y., Wolkenhauer, O., Kottek, T., Bhattacharya, A., Simon, J. C., & Kunz, M. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.01.020 · Cited by 44
Zhang, R., Shi, H., Ren, F., Liu, H., Zhang, M., Deng, Y., & Li, X. (2015) · Oncology Reports · doi:10.3892/or.2015.3723 · Cited by 44
Rammah, M., Dandachi, F., Salman, R., Shihadeh, A., & El-Sabban, M. E. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.04.003 · Cited by 44
BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling
Liu, X., Tian, X., Wang, F., Ma, Y., Kornmann, M., & Yang, Y. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.05.017 · Cited by 44
2-Azetidinones: Synthesis and biological evaluation as potential anti-breast cancer agents
Geesala, R., Gangasani, J. K., Budde, M., Sridhar, B., Vaidya, J. R., & Das, A. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.041 · Cited by 44
Serine/arginine-rich splicing factor 7 regulates p21-dependent growth arrest in colon cancer cells
Saijo, S., Kuwano, Y., Masuda, K., Nishikawa, T., Rokutan, K., & Nishida, K. (2016) · The Journal of Medical Investigation · doi:10.2152/jmi.63.219 · Cited by 44
Troncone, M. J., Cargnelli, S., Villani, L. A., Isfahanian, N., Broadfield, L. A., Zychla, L., Wright, J., Pond, G. R., Steinberg, G. R., & Tsakiridis, T. K. (2017) · Oncotarget · doi:10.18632/oncotarget.17496 · Cited by 45
Silva, M. D. F., Coelho, L. F., Guirelli, I. M., Pereira, R. M., Ferreira‐Silva, G. Á., Graravelli, G. Y., Horvath, R. D. O., Caixeta, E. S., Ionta, M., & Viegas, C. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.02.020 · Cited by 44
Xia, P., Liu, Y., Chen, J., Coates, S., Liu, D. X., & Cheng, Z. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004673 · Cited by 44
ITGB 4 deficiency induces senescence of airway epithelial cells through p53 activation
Yuan, L., Du, X., Tang, S., Wu, S., Wang, L., Xiang, Y., Qu, X., Liu, H., Qin, X., & Liu, C. (2019) · FEBS Journal · doi:10.1111/febs.14749 · Cited by 44
CRL4Cdt2: Coupling Genome Stability to Ubiquitination
Παναγόπουλος, Α., Taraviras, S. L., Nishitani, H., & Lygerou, Z. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.01.005 · Cited by 42
Yoon, Y. N., Lee, D.-S., Park, H. J., & Kim, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-59445-x · Cited by 44
The regulation of radiosensitivity by p53 and its acetylation
Zhang, J., Shen, L., & Sun, L. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.015 · Cited by 45
Inaba, H., Kuboniwa, M., Sugita, H., Lamont, R. J., & Amano, A. (2012) · Infection and Immunity · doi:10.1128/iai.00258-12 · Cited by 46
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma
Ishio, T., Kumar, S., Shimono, J., Daenthanasanmak, A., Dubois, S. P., Lin, Y., Bryant, B. R., Petrus, M. N., Bachy, E., Huang, D. W., et al. (2021) · Blood · doi:10.1182/blood.2021012734 · Cited by 41
Huang, Y., Zhu, Y., Yang, J., Pan, Q., Zhao, J., Song, M., Yang, C., Han, Y., Tang, Y., Wang, Q., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04676-1 · Cited by 43
Klepacki, H., Kowalczuk, K., Łepkowska, N., & Hermanowicz, J. M. (2025) · Cells · doi:10.3390/cells14130942 · Cited by 49
The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression
Fenouille, N., Robert, G., Tichet, M., Puissant, A., Dufies, M., Rocchi, S., Ortonne, J. P., Deckert, M., Ballotti, R., & Tartare‐Deckert, S. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00790.x · Cited by 47
Luo, J., Zhou, X., Ge, X., Liu, P., Cao, J., Lu, X., Ling, Y., & Zhang, S. (2013) · Cancer Science · doi:10.1111/cas.12248 · Cited by 43
Han, Y., Kee, J., Kim, D., Mun, J., Jeong, M., Park, S.-H., Choi, B., Park, S., Kim, H. J., Um, J., et al. (2016) · Molecules · doi:10.3390/molecules21091135 · Cited by 43
Kapral, M., Wawszczyk, J., Jesse, K., Paul-Samojedny, M., Kuśmierz, D., & Węglarz, L. (2017) · Molecules · doi:10.3390/molecules22101657 · Cited by 43
Inoue, Y., Kawachi, S., Ohkubo, T., Nagasaka, M., Ito, S., Fukuura, K., Itoh, Y., Ohoka, N., Morishita, D., & Hayashi, H. (2017) · FEBS Letters · doi:10.1002/1873-3468.12869 · Cited by 44
Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma
Zhao, X., Reebye, V., Hitchen, P. G., Fan, J., Jiang, H., Sætrom, P., Rossi, J. J., Habib, N. A., & Huang, K. (2019) · Oncogene · doi:10.1038/s41388-018-0665-6 · Cited by 43
Dabiri, Y., el Maaty, M. A. A., Chan, H. Y., Wölker, J., Ott, I., Wölfl, S., & Cheng, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00438 · Cited by 44
Joshi, G., Kalra, S., Yadav, U. P., Sharma, P., Singh, P. K., Amrutkar, S. M., Ansari, A. J., Kumar, S., Sharon, A., Sharma, S., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103409 · Cited by 43
Niu, H., Huang, Y., Li, Y., Zhang, L., Zhao, M., Lu, T., Yang, X., Chen, Z., Zhan, C., Shi, Y., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.40173 · Cited by 43
Kurosu, T., Wu, N., Oshikawa, G., Kagechika, H., & Miura, O. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0457-0 · Cited by 43
Casafont, Í., Palanca, A., Lafarga, V., Berciano, M. T., & Lafarga, M. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0869-0 · Cited by 44
Overcoming Chemotherapy Resistance in Germ Cell Tumors
Országhová, Z., Kaľavská, K., Mego, M., & Chovanec, M. (2022) · Biomedicines · doi:10.3390/biomedicines10050972 · Cited by 42
Liu, H., Zhang, W., Jin, L., Liu, S., Liang, L., & Wei, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076279 · Cited by 43
Calderon, M. R., Verway, M. J., An, B., DiFeo, A. V., Bismar, T. A., Ann, D. K., Martignetti, J. A., Shalom‐Barak, T., & White, J. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311605 · Cited by 43
Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis
Chen, Y.-C., Chan, J. Y., Chiu, Y.-L., Liu, S. T., Lozano, G., Wang, S. L., Ho, C.-L., & Huang, S.-M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.1 · Cited by 42
Bastian, L., Hof, J., Pfau, M., Fichtner, I., Eckert, C., Henze, G., Prada, J., von Stackelberg, A., Seeger, K., & Shalapour, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1511 · Cited by 43
Chu, K., Gao, G., Yang, X., Ren, S., Li, Y., Wu, H., Huang, Y., & Zhou, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3279 · Cited by 42
SOX5/6/21 Prevent Oncogene-Driven Transformation of Brain Stem Cells
Kurtsdotter, I., Topcic, D., Karlén, A., Singla, B., Hagey, D. W., Bergsland, M., Siesjö, P., Nistér, M., Carlson, J. W., Lefebvre, V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0704 · Cited by 45
Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by reducing p21 levels
Huang, J., Deng, G., Liu, T., Chen, W., & Zhou, Y. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.157 · Cited by 42
Bavachalcone from Cullen corylifolium induces apoptosis and autophagy in HepG2 cells
Song, H. S., Jang, S., & Kang, S. C. (2017) · Phytomedicine · doi:10.1016/j.phymed.2017.12.030 · Cited by 42
Wang, A., Wang, S., Zhou, F., Li, P., Wang, Y., Gan, L., & Lin, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.094 · Cited by 42
Cold atmospheric plasma treatment inhibits growth in colorectal cancer cells
Schneider, C., Arndt, S., Zimmermann, J. L., Li, Y., Karrer, S., & Bosserhoff, A. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0193 · Cited by 42
Rosas‐González, V. C., Téllez‐Bañuelos, M. C., Hernández‐Flores, G., Bravo‐Cuéllar, A., Aguilar‐Lemarroy, A., Jave‐Suárez, L. F., Haramati, J., Ibarra, F. S., & Ortiz‐Lazareno, P. C. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12559 · Cited by 43
Silencing Sirtuin 6 induces cell cycle arrest and apoptosis in non-small cell lung cancer cell lines
Krishnamoorthy, V., & Ravikumar, V. (2020) · Genomics · doi:10.1016/j.ygeno.2020.04.027 · Cited by 42
Irisin, an exercise myokine, potently suppresses tumor proliferation, invasion, and growth in glioma
Huang, C., Chang, Y., Lee, H., Wu, J., Huang, J., Chung, Y., Hsu, S.-T., Chow, L., Wei, K., & Huang, F. (2020) · The FASEB Journal · doi:10.1096/fj.202000573rr · Cited by 43
Lee, J., Kim, K., Ryu, T. Y., Jung, C., Lee, M., Lim, J. H., Park, K., Kim, D., Son, M., Hamamoto, R., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13050 · Cited by 42
Anastasis: Return Journey from Cell Death
Zaitceva, V., Kopeina, G. S., & Zhivotovsky, B. (2021) · Cancers · doi:10.3390/cancers13153671 · Cited by 41
Costunolide: A novel anti-cancer sesquiterpene lactone
Rasul, A., Parveen, S., & Ma, T. (2012) · Bangladesh Journal of Pharmacology · doi:10.3329/bjp.v7i1.10066 · Cited by 42
Wang, Z., Zhang, Y.-D., Gu, J., Davitt, C., Reeves, R., & Magnuson, N. (2010) · International Journal of Biochemistry and Cell Biology · doi:10.1016/j.biocel.2010.03.012 · Cited by 44
Differential cell-cycle control by oscillatory versus sustained Hes1 expression via p21
Maeda, Y., Isomura, A., Masaki, T., & Kageyama, R. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112520 · Cited by 40
Maternal Embryonic Leucine Zipper Kinase (MELK) Reduces Replication Stress in Glioblastoma Cells
Kığ, C., Beullens, M., Beke, L., Eynde, A. V., Linders, J. T., Brehmer, D., & Bollen, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.471433 · Cited by 40
RetractedDing, L., Huang, Y., Dai, M., Zhao, X., Du, Q., Dong, F., Wang, L., Huo, R., Zhang, W., Xu, X., et al. (2013) · Virus Research · doi:10.1016/j.virusres.2013.09.036 · Cited by 41
Esteve‐Puig, R., Gil, R., González‐Sánchez, E., Bech‐Serra, J. J., Grueso, J., Hernández‐Losa, J., Moliné, T., Canals, F., Fábrega, B. F., Cortés, J., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004721 · Cited by 42
Lin, H., Wang, Y., & Chiang, C. (2010) · Head & Neck · doi:10.1002/hed.21452 · Cited by 41
Fiore, R. D., Drago‐Ferrante, R., Pentimalli, F., Marzo, D. D., Forte, I. M., Carlisi, D., BLASIO, A. D., Tesoriere, G., Giordano, A., & Vento, R. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25291 · Cited by 41
Metadata
- Authors
- Abbas, T., & Dutta, A.
- Affiliations
- University of Virginia (US)
- Corresponding author
- Abbas, Tarek
- Dutta, Anindya
- Venue
- Nature Reviews Cancer
- Published
- 2009-05-14
- Volume
- 9
- Issue
- 6
- Pages
- 400-414
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC2722839
- OpenAlex
- W2162262059
- Cited by
- 2,712
- References
- 236
- Citations by year
- 2026: 99 · 2025: 156 · 2024: 161 · 2023: 206 · 2022: 182 · 2021: 205 · 2020: 204 · 2019: 180 · 2018: 191 · 2017: 196 · 2016: 148 · 2015: 160 · 2014: 142 · 2013: 151 · 2012: 122
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA089406, R01 CA 89406, T32CA009109)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p21, cyclin-dependent kinase inhibitors, cell cycle arrest, therapeutic target, cell transformation
- MeSH terms
- Animals, Cell Cycle, Humans, Neoplasms, Tumor Suppressor Protein p53, Cyclin-Dependent Kinase Inhibitor p21
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
